But the FDA and the Centers for Disease Control and Prevention (CDC) released a safety notice on May 9 recommending that adults over 60 years old pause use of the vaccine due to fatal complications.

Chikungunya isn't prevalent in the U.S., but travelers are being told to be cautious about getting the vaccine for the ...

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

An infection with the virus is rarely fatal but can result in persistent joint pain. About 200 cases of chikungunya were reported in the U.S. in 2024; all of them were travel-associated. The Food and ...

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

The FDA and CDC recommended the pause while the government looks into possible side effects. Also: RFK Jr. raises eyebrows after swimming with his grandkids in a contaminated creek; President Donald ...

Federal health officials are advising Americans aged 60 and older to avoid the chikungunya vaccine Ixchiq amid an ...

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health ...

The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a ...

Hold off on inoculating people ages 60 and older against chikungunya infection with the Ixchiq vaccine, the FDA and CDC jointly recommended amidst an investigation into adverse events.